CCD 3045 neuroactive steroid acting at GABA receptors data

A Phase I study of CCD 3045 in France showed inadequate blood levels of the drug, leading the company to abandon it in favor of an improved molecule more resistant to liver metabolism.

Animal studies of the sedative did show inter-species variability in how quickly the drug was being metabolized, which is typical with steroids, said President and CEO Daniel Korpolinski. While the drug put people to sleep when injected, oral doses were being rapidly inactivated by the liver, he said. ...